Vikram Purohit

Stock Analyst at Morgan Stanley

(1.81)
# 3,310
Out of 5,148 analysts
163
Total ratings
32.31%
Success rate
-7.58%
Average return

Stocks Rated by Vikram Purohit

COMPASS Pathways
Feb 18, 2026
Maintains: Overweight
Price Target: $11$18
Current: $7.02
Upside: +156.41%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92$94
Current: $100.04
Upside: -6.04%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31$34
Current: $25.56
Upside: +33.02%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80$79
Current: $69.85
Upside: +13.10%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4$5.89
Current: $2.80
Upside: +110.36%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.63
Upside: +37.74%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180$250
Current: $242.09
Upside: +3.27%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125$190
Current: $166.38
Upside: +14.20%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6$9
Current: $5.76
Upside: +56.25%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $29.65
Upside: +4.55%
Maintains: Equal-Weight
Price Target: $15$16
Current: $113.11
Upside: -85.85%
Maintains: Overweight
Price Target: $45$10
Current: $24.76
Upside: -59.61%
Downgrades: Equal-Weight
Price Target: $46$6
Current: $13.98
Upside: -57.08%
Maintains: Overweight
Price Target: $43$42
Current: $9.24
Upside: +354.55%
Maintains: Equal-Weight
Price Target: $38$41
Current: $90.10
Upside: -54.50%
Maintains: Equal-Weight
Price Target: $120$40
Current: $8.58
Upside: +366.20%
Initiates: Equal-Weight
Price Target: $13
Current: $2.31
Upside: +462.77%
Maintains: Equal-Weight
Price Target: $39$38
Current: $12.15
Upside: +212.76%
Maintains: Equal-Weight
Price Target: $24$20
Current: $7.05
Upside: +183.69%
Maintains: Underweight
Price Target: $11$10
Current: $18.95
Upside: -47.23%
Initiates: Overweight
Price Target: $22
Current: $1.05
Upside: +1,995.24%
Maintains: Equal-Weight
Price Target: $40$20
Current: $23.25
Upside: -13.98%